Cargando…
The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs...
Autores principales: | Zhang, Jishou, Wang, Menglong, Ding, Wen, Wan, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377983/ https://www.ncbi.nlm.nih.gov/pubmed/32712300 http://dx.doi.org/10.1016/j.lfs.2020.118142 |
Ejemplares similares
-
COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021) -
Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021) -
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020) -
RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021) -
Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)